Literature DB >> 12153177

Immunophenotypic profile of AC133-positive cells in bone marrow, mobilized peripheral blood and umbilical cord blood.

Giovanni D'Arena1, Lucia Savino, Giuseppe Nunziata, Nicola Cascavilla, Rosella Matera, Giuseppe Pistolese, Angelo Michele Carella.   

Abstract

AC133 is a molecule whose expression in the human hematopoietic system is restricted to a subset of CD34+ progenitor/stem cells with long-term repopulating ability. The antigenic features of these cells, like CD34+ cells, are described heterogeneous. The immunophenotypic profile of AC133+ cells, detected by means of dual-color flow cytometry, in bone marrow (BM), cytokine-mobilized peripheral blood (PB) and umbilical cord blood (UCB) was evaluated. The highest percentage of AC133+ cells was detected in mobilized PB despite not significantly different from that found in BM, but both are higher than that found in UCB. In addition, the highest percentage of CD34, HLA-DR and CD33 co-expressing AC133+ cells was observed in mobilized PB. Furthermore, UCB was found to be enriched in CD7+ and CD19+ cells and BM was found to be enriched in AC133+ cells co-expressing CDw90 and CD71. Our data confirm the immunophenotypic heterogeneity of cells expressing AC133 antigen, a promising new stem cell marker to be increasingly used as additional target for alternative identification and separation of early hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153177     DOI: 10.1080/10428190290017015

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.

Authors:  Elisabet Björklund; Astrid Gruber; Joanna Mazur; Anna Mårtensson; Mona Hansson; Anna Porwit
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

2.  Premobilization of CD133+ cells by granulocyte colony- stimulating factor attenuates ischemic acute kidney injury induced by cardiopulmonary bypass.

Authors:  Xiaoqiang Li; Qin Wan; Jie Min; Linjia Duan; Jin Liu
Journal:  Sci Rep       Date:  2019-02-21       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.